Linked Life Data

15709924

Source:http://linkedlifedata.com/resource/pubmed/id/15709924

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15709924rdf:typepubmed:Citationlld:pubmed
pubmed-article:15709924lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0022658lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0024141lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0262926lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C1517205lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0040223lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0332119lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0021149lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C0205164lld:lifeskim
pubmed-article:15709924lifeskim:mentionsumls-concept:C2828297lld:lifeskim
pubmed-article:15709924pubmed:issue1lld:pubmed
pubmed-article:15709924pubmed:dateCreated2005-2-15lld:pubmed
pubmed-article:15709924pubmed:abstractTextThe safety and efficacy of abetimus sodium (abetimus) has been evaluated in 13 controlled and uncontrolled clinical trials involving > 800 patients or subjects. The two pivotal trials enrolled a total of 547 patients with systemic lupus erythematosus (SLE) who had a history of lupus nephritis. Evidence of clinical effectiveness of abetimus comes from analyses of data from patients with SLE and high-affinity antibodies to the DNA epitope of abetimus at baseline; a retrospective subgroup in the pivotal Phase II/III LJP-394-90-05 trial (90-05 trial) and the intent-to-treat population in the Phase III LJP-394-90-09 trial (90-09 trial). These studies enrolled SLE patients who had experienced prior renal manifestations of their disease and had elevated anti-dsDNA antibodies at baseline by Farr assay. Both were long-term studies, with a mean duration of treatment participation of 371 days in 90-05 and 310 days in 90-09 for the population of patients with high-affinity antibodies at baseline. The 90-05 and 90-09 studies, as well as all other clinical studies of abetimus, consistently showed that treatment with abetimus resulted in durable and persistent reductions in anti-dsDNA antibodies in SLE patients. Treatment with abetimus was associated with statistically significant decreases in anti-dsDNA antibody levels from baseline compared with placebo in both the 90-09 and 90-05 trials. Positive trends were noted for the incidence of renal flares and major SLE flares in patients treated with abetimus. Abetimus appeared to be well tolerated for treatment periods of < or = 22 months.lld:pubmed
pubmed-article:15709924pubmed:languageenglld:pubmed
pubmed-article:15709924pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15709924pubmed:citationSubsetIMlld:pubmed
pubmed-article:15709924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15709924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15709924pubmed:statusMEDLINElld:pubmed
pubmed-article:15709924pubmed:monthJanlld:pubmed
pubmed-article:15709924pubmed:issn1744-7658lld:pubmed
pubmed-article:15709924pubmed:authorpubmed-author:CardielMario...lld:pubmed
pubmed-article:15709924pubmed:issnTypeElectroniclld:pubmed
pubmed-article:15709924pubmed:volume14lld:pubmed
pubmed-article:15709924pubmed:ownerNLMlld:pubmed
pubmed-article:15709924pubmed:authorsCompleteYlld:pubmed
pubmed-article:15709924pubmed:pagination77-88lld:pubmed
pubmed-article:15709924pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15709924pubmed:meshHeadingpubmed-meshheading:15709924...lld:pubmed
pubmed-article:15709924pubmed:meshHeadingpubmed-meshheading:15709924...lld:pubmed
pubmed-article:15709924pubmed:meshHeadingpubmed-meshheading:15709924...lld:pubmed
pubmed-article:15709924pubmed:meshHeadingpubmed-meshheading:15709924...lld:pubmed
pubmed-article:15709924pubmed:meshHeadingpubmed-meshheading:15709924...lld:pubmed
pubmed-article:15709924pubmed:meshHeadingpubmed-meshheading:15709924...lld:pubmed
pubmed-article:15709924pubmed:meshHeadingpubmed-meshheading:15709924...lld:pubmed
pubmed-article:15709924pubmed:year2005lld:pubmed
pubmed-article:15709924pubmed:articleTitleAbetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease.lld:pubmed
pubmed-article:15709924pubmed:affiliationHospital General Dr Miguel Silva, Isidro Huarte y Samuel Ramos S/N, Morelia, Michoacán, CP 58000, México. morrelia@att.net.mxlld:pubmed
pubmed-article:15709924pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15709924pubmed:publicationTypeReviewlld:pubmed